MEKSIKOR (Capsules)
Active material: эtilmetilgidroksipiridina succinate
When ATH: C01EB
CCF: Antioxidant drugs
ICD-10 codes (testimony): E78.5, F07, G93.4, i20, I20.0, I21, I61, I63, I67.2, I69
When CSF: 01.12.11.04
Manufacturer: ÈkoFarmInvest LLC (Russia)
Pharmaceutical form, composition and packaging
Capsules hard gelatin, size №2, yellow color; contents of capsules – granules, consisting of granules and powder white or white with a yellowish Sheen color.
| 1 caps. | |
| эtilmetilgidroksipiridina succinate | 100 mg |
Excipients: potato starch, povidone (polivinilpirrolidon low medical 12600 2700 ±), lactose, magnesium stearate, microcrystalline cellulose.
Ingredients of the capsule shell: Titanium dioxide (E171), gelatin, colorant sunset yellow (E110), quinoline yellow dye (E104).
10 PC. – packings Valium planimetric (2) – packs cardboard.
10 PC. – packings Valium planimetric (5) – packs cardboard.
Pharmacological action
Antioxidant drugs, possessing an anti-ischemic, is an antianginal, antihypoxic, angioprotektornym, gipoholesterinemičeskim, anxiolytic and nootropic effect, regulates metabolic processes miocarde and vascular wall.
Meksikor® reduces oxidative stress, braking free radical lipid peroxidation and increasing the activity of the antioxidant system of enzymes. Meksikor® improves cellular energy exchange, activating the ènergosinteziruûŝie function of mitochondria, increasing compensatory activation of aerobic Glycolysis and reducing the degree of oppression oxidizing processes in the cycle of Krebsa.
Ènergosinteziruûŝee effect of the drug is linked to the increase in the delivery and consumption of cells succinate, implementation of rapid phenomenon of oxidation of succinic acid sukcinatdegidrogenazoj, as well as the activation of the mitochondrial respiratory chain. When dissociation Meksikora® in a cage on succinate and derivative of 3-oksipiridina (ground), the Foundation has shown powerful antioxidant effects, stabilizing cell membranes and regenerating the functional activity of cells. Meksikor® decreases viscosity of the cell membrane, increases its turnover and provides modulation effect on the membrane enzymes (calcium-independent fosfodiesterzu, adenylyl Cyclase, azetilholinesterzu), ion channels and receptor complexes, that contributes to the conservation of structural and functional integrity of biomembranes, improves transport of neurotransmitters and sinapticescuu transfer.
The drug improves cerebral metabolism and blood circulation of the brain, improves microcirculation and blood rheology, reduces platelet aggregation. It has hypolipidemic effect, reduces the total cholesterol and LDL.
Meksikor® improves functional status of išemizirovannogo infarction, reducing manifestation of systolic and diastolic left ventricular dysfunction, as well as electrical instability of the myocardium. In terms of coronary insufficiency Meksikor® increases blood flow to the myocardium ishemizirovannogo collateral and activates jenergosintezirujushhie processes in the area of ischemia, that contributes to the preservation of the integrity of cardiomyocytes and keeping them functional activity. Meksikor® effectively restores the airway diseases in reversible cardiac dysfunction, caused by States “hibernation” (hibernation) and “oglušennosti” infarction, that represents a substantial reserve increase the contractility of the heart in patients with ischemic heart disease, complicated heart failure.
In patients with stable exertional angina Meksikor® increases tolerance to physical activity and antianginalnuu activity of nitrates, improves blood rheology, reduces the incidence of acute coronary insufficiency.
Add Meksikora® the standard therapy of patients with ISCHEMIC HEART DISEASE with chronic heart failure has a positive effect on the clinical condition of patients, increasing tolerance for endurance and improving quality of life.
Meksikor® increases the effectiveness of therapy due to scale their own scale activity and ability to reduce the likelihood of Cardial side effects major complications drugs, preserving or enhancing their specific activity.
Meksikor® stabilizes the membrane structure of the vascular wall, It inhibits platelet aggregation, normalizes microcirculation infringements in the early stages of atherogenesis, provides lipidkorrigiruûŝee effect on the ratio of Pro- and antiaterogennah fractions of blood lipids, lowering cholesterol levels, VLDL, LDL and triglycerides, while raising HDL-Xc.
Use Meksikora® in patients with diabetes mellitus type 2 reduces the blood levels of total cholesterol, triglycerides, lipid peroxidation products, as well as increases the activity of enzymes of antioxidative defense (superoksiddismutazы, glutathione peroxidase and catalase), while increasing the functional activity of β-islet cells of the pancreas. Reducing insulin resistance and improved compensation of diabetes during treatment with Mexicor®, as evidenced by a decrease in blood glucose levels and glycated hemoglobin, It reduces the risk of micro- and macroangiopathies.
Use Meksikora® in the treatment of patients with coronary artery disease and hypertension crisis course shortens postkrizovoy stabilization, reduces the chance of recurrence and frequency development gipertoniceski kriza acute coronary insufficiency amid crisis, increases gipotenzivny effect of ACE inhibitors and beta blockers.
Meksikor® nootropnami properties, prevents and reduces violations of learning processes and memory, arising in acute and chronic vascular diseases of the brain and aging, in light and moderate cognitive violations of various Genesis, provides antihypoxia effect, improves concentration and performance.
Enable Meksikora® in the complex treatment of patients with acute violation of cerebral circulation reduces the severity of clinical manifestations of stroke and improves during rehabilitation period.
Meksikor® has a selective, not accompanied by a sedative effect and miorelaksaciei, anxiolytic action, eliminates anxiety, fear, voltage, anxiety, improves adapt and emotional status.
Pharmacokinetics
Absorption
After intake of the active substance of the preparation Meksikor® quickly and completely absorbed from the digestive tract. The time to reach Cmax in plasma is 0.46-0.50 no. The Value Of Cmax is in the range from 50 to 100 ng / ml. Poluabsorbcii period is 0.08-0.10 no.
Metabolism
Biotransformiroetsa intensively in the liver with the formation of phosphate-3-oksipiridina and gljukuronokon'jugirovannyh products.
Deduction
T1/2 and the average holding time drug in the body are respectively 4.7-5.0 and h 4.9-5.2 no. Average, for 12 h the urine output 0.3% unchanged drug and 50% of the administered dose – as glûkuronokon″ûgata. The most intensely active substance and its gljukuronokon'jugaty are displayed in the first 4 h after dosing.
Testimony
- In the complex treatment of coronary artery disease (stable stenocardia voltage, unstable angina, Acute myocardial infarction);
- CHD, abnormal arterial hypertension krizovogo currents, chronic insufficiency of blood circulation, išemičeskimi ventricular arrhythmias;
- Acute cerebrovascular accident;
- Encephalopathy (incl. atherosclerotic Genesis);
light and moderate cognitive disorders of different Genesis;
— intellectual and memory disorders in patients of elderly and senile age;
-atherogenic dislipoproteidemii.
Dosage regimen
Meksikor® appointed interior. Applied therapeutic dose and duration of treatment determined by Nosological form of the disease and the patient's sensitivity to the drug.
The initial dose is 100 mg 3 times / day. Next, you will gradually increase the dose until the therapeutic effect. The maximum daily dose should not exceed 800 mg, single – 200 mg. Daily dose of the drug, it is desirable to distribute to 3 receiving during the day.
Duration of therapy Meksikorom® When you apply it in the complex treatment of coronary artery disease must be at least 1.5-2 Months. We recommend carrying out 2 a two-month course of therapy during the year, in spring and autumn periods.
At CHD, complicated by arterial hypertension krizovogo currents, chronic insufficiency of blood circulation, išemičeskimi ventricular arrhythmias; patients diabetes mellitus type 2, at dyscirculatory encephalopathy, light and moderate cognitive disorders, as well as with correction of dislipoproteidemii Meksikor® appointed without limiting treatment duration, dose 100 mg 3-4 times / day.
The course of treatment Meksikorom® finish gradually, reducing the daily dose of the drug to the 100 mg.
Side effect
From the digestive system: rarely – dry mouth, nausea, dyspepsia, that quickly disappear on their own or denial of drug; prolonged use – flatulence.
Other: rarely – allergic reactions.
Contraindications
- Acute liver dysfunction;
- Acute renal dysfunction;
- Childhood and adolescence up 18 years;
- Pregnancy;
- Lactation (breast-feeding);
- Hypersensitivity to the drug.
Pregnancy and lactation
We do not recommend the use of drugs in pregnancy and lactation because of insufficient knowledge of the drug during these periods.
Cautions
With the utmost caution should appoint Meksikor® patients with a history of allergological history.
Use in Pediatrics
Efficacy and safety of Meksikora assignment® children and adolescents under the age of 18 years not set.
Effects on ability to drive vehicles and management mechanisms
At the beginning of treatment is advisable to refrain from activities potentially hazardous activities, require high concentration and speed of psychomotor reactions.
Overdose
With regard to the low toxicity of the drug overdose unlikely.
Symptoms: in case of accidental overdose, you may experience symptoms of sleep disorders – drowsiness, insomnia.
Treatment: symptomatic therapy.
Drug Interactions
Meksikor® reinforces the effect protivosudorozhnykh funds (Carbamazepine), antiparkinsonian (levodopa) and benzodiazepine anxiolytics.
Meksikor® improves antianginalnuu activity of nitrates and antihypertensive activity of ACE inhibitors and beta blockers.
Combined use of Meksikora® with nibentanom, propranolol and verapamil reduces the risk of developing aritmogennyh effects last.
Conditions of supply of pharmacies
The drug is released under the prescription.
Conditions and terms
List B. The drug should be stored out of reach of children, dry, dark place at a temperature no higher than 25 ° C. Shelf life - 3 year.
